Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA.

Urology. 2018 Feb 9. pii: S0090-4295(18)30093-1. doi: 10.1016/j.urology.2018.01.036. [Epub ahead of print]

PMID:
29432873
2.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ.

J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31.

PMID:
29384722
3.

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.

Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, Hahn NM, McConkey D, Bivalacqua TJ, Pierorazio PM.

J Urol. 2018 Jan 4. pii: S0022-5347(18)30003-X. doi: 10.1016/j.juro.2017.12.054. [Epub ahead of print]

PMID:
29307680
4.

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS.

Clin Genitourin Cancer. 2017 Dec 6. pii: S1558-7673(17)30364-6. doi: 10.1016/j.clgc.2017.11.004. [Epub ahead of print]

PMID:
29289519
5.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
6.

YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.

Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ, Rasheed ZA, Mao S, Netto GJ, Sidransky D, Hoque MO.

Cancer Res. 2018 Jan 1;78(1):168-181. doi: 10.1158/0008-5472.CAN-17-0836. Epub 2017 Nov 27.

PMID:
29180467
7.

Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA.

Ann Nucl Med. 2018 Jan;32(1):69-74. doi: 10.1007/s12149-017-1216-x. Epub 2017 Oct 24.

PMID:
29067547
8.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J.

Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.

PMID:
28967485
9.

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.

Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ.

Bladder Cancer. 2017 Jul 27;3(3):145-146. doi: 10.3233/BLC-170118. No abstract available.

10.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

PMID:
28817753
11.

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ.

Clin Cancer Res. 2017 Nov 1;23(21):6592-6601. doi: 10.1158/1078-0432.CCR-17-1082. Epub 2017 Aug 14.

PMID:
28808039
12.

Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ.

Cancer Immunol Res. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6.

13.

Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.

Fulkerson CM, Dhawan D, Ratliff TL, Hahn NM, Knapp DW.

Int J Genomics. 2017;2017:6589529. doi: 10.1155/2017/6589529. Epub 2017 Apr 9. Review.

14.

Port Site Recurrence Following a Robotic Laparoscopic Radical Nephroureterectomy for Sarcomatoid Variant of Urothelial Carcinoma.

Katz JE, Bivalacqua TJ, Hahn NM, Sopko NA.

Urol Case Rep. 2017 Apr 27;13:82-84. doi: 10.1016/j.eucr.2016.10.015. eCollection 2017 Jul.

15.

Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.

Chappidi MR, Kates M, Tosoian JJ, Johnson MH, Hahn NM, Bivalacqua TJ, Pierorazio PM.

BJU Int. 2017 Sep;120(3):377-386. doi: 10.1111/bju.13878. Epub 2017 May 17.

PMID:
28418183
16.

Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer.

Chappidi MR, Kates M, Brant A, Baras AS, Netto GJ, Pierorazio PM, Hahn NM, Bivalacqua TJ.

Urology. 2017 Apr;102:148-158. doi: 10.1016/j.urology.2016.10.064. Epub 2017 Jan 16.

17.

Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.

Thomas DE, Kaimakliotis HZ, Rice KR, Pereira JA, Johnston P, Moore ML, Reed A, Cregar DM, Franklin C, Loman RL, Koch MO, Bihrle R, Foster RS, Masterson TA, Gardner TA, Sundaram CP, Powell CR, Beck SDW, Grignon DJ, Cheng L, Albany C, Hahn NM.

Clin Genitourin Cancer. 2017 Aug;15(4):479-486. doi: 10.1016/j.clgc.2016.11.009. Epub 2016 Nov 30.

18.

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.

Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM.

Clin Cancer Res. 2017 Jun 15;23(12):3003-3011. doi: 10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8.

PMID:
27932416
19.

New treatments for bladder cancer.

Hahn NM.

Clin Adv Hematol Oncol. 2016 Nov;14(11):884-887. No abstract available.

PMID:
27930639
20.

Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.

Park JC, Hahn NM.

Urol Oncol. 2016 Dec;34(12):566-576. doi: 10.1016/j.urolonc.2016.09.002. Epub 2016 Oct 20. Review.

PMID:
27773553
21.

Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?

Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, Netto GJ, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ.

Urol Oncol. 2017 Jan;35(1):34.e17-34.e25. doi: 10.1016/j.urolonc.2016.08.005. Epub 2016 Sep 14.

PMID:
27639777
22.

Infectious complications in transfused patients after radical cystectomy.

Liu JJ, Mullane P, Kates M, Gandhi N, Schoenberg MP, Drake C, Hahn NM, Frank S, Bivalacqua TJ.

Can J Urol. 2016 Aug;23(4):8342-7.

PMID:
27544556
23.

Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012).

Chappidi MR, Kates M, Johnson MH, Hahn NM, Bivalacqua TJ, Pierorazio PM.

Urol Oncol. 2016 Dec;34(12):531.e15-531.e24. doi: 10.1016/j.urolonc.2016.06.013. Epub 2016 Jul 27.

24.

Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select.

Drake CG, Bivalacqua TJ, Hahn NM.

J Clin Oncol. 2016 Sep 10;34(26):3115-6. doi: 10.1200/JCO.2016.68.4696. Epub 2016 Jul 25. No abstract available.

PMID:
27458310
25.

National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.

Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER.

J Clin Oncol. 2016 Sep 20;34(27):3346-8. doi: 10.1200/JCO.2016.68.1429. Epub 2016 Jul 25. No abstract available.

26.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

27.

Bladder cancer.

Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W.

Lancet. 2016 Dec 3;388(10061):2796-2810. doi: 10.1016/S0140-6736(16)30512-8. Epub 2016 Jun 23. Review. Erratum in: Lancet. 2016 Dec 3;388(10061):2742.

PMID:
27345655
28.

Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.

Kaimakliotis HZ, Monn MF, Cho JS, Pedrosa JA, Hahn NM, Albany C, Gellhaus PT, Cary KC, Masterson TA, Foster RS, Bihrle R, Cheng L, Koch MO.

Future Oncol. 2016 Aug;12(15):1795-804. doi: 10.2217/fon-2016-0056. Epub 2016 Jun 3.

PMID:
27255805
29.

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.

Graff JN, Higano CS, Hahn NM, Taylor MH, Zhang B, Zhou X, Venkatakrishnan K, Leonard EJ, Sarantopoulos J.

Cancer. 2016 Aug 15;122(16):2524-33. doi: 10.1002/cncr.30073. Epub 2016 May 18.

30.

Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy.

Chalfin HJ, Liu JJ, Gandhi N, Feng Z, Johnson D, Netto GJ, Drake CG, Hahn NM, Schoenberg MP, Trock BJ, Scott AV, Frank SM, Bivalacqua TJ.

Ann Surg Oncol. 2016 Aug;23(8):2715-22. doi: 10.1245/s10434-016-5193-4. Epub 2016 Mar 24.

PMID:
27012987
31.

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Ghasemzadeh A, Bivalacqua TJ, Hahn NM, Drake CG.

Clin Cancer Res. 2016 Feb 15;22(4):793-801. doi: 10.1158/1078-0432.CCR-15-1135. Epub 2015 Dec 18. Review.

32.

A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.

Park JC, Gandhi NM, Carducci MA, Eisenberger MA, Baras AS, Netto GJ, Liu JJ, Drake CG, Schoenberg MP, Bivalacqua TJ, Hahn NM.

J Urol. 2016 Apr;195(4 Pt 1):880-5. doi: 10.1016/j.juro.2015.11.024. Epub 2015 Nov 18.

PMID:
26598426
33.

Immune checkpoint inhibitors: a new frontier in bladder cancer.

Kates M, Sopko NA, Matsui H, Drake CG, Hahn NM, Bivalacqua TJ.

World J Urol. 2016 Jan;34(1):49-55. doi: 10.1007/s00345-015-1709-y. Epub 2015 Oct 20. Review.

PMID:
26487055
34.

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1259-65. doi: 10.1007/s00280-015-2884-7. Epub 2015 Oct 13.

PMID:
26464352
35.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G.

Urol Oncol. 2016 Jan;34(1):4.e11-7. doi: 10.1016/j.urolonc.2015.08.005. Epub 2015 Sep 9.

PMID:
26362343
36.

Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.

Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu JJ, Kates M, Hoque MO, Berman D, Hahn NM, Eisenberger M, Netto GJ, Schoenberg MP, Bivalacqua TJ.

Urol Oncol. 2015 May;33(5):204.e1-7. doi: 10.1016/j.urolonc.2015.02.011. Epub 2015 Mar 23.

37.

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.

Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T.

Clin Cancer Res. 2015 Aug 1;21(15):3420-7. doi: 10.1158/1078-0432.CCR-14-3370. Epub 2015 Mar 18.

38.

Bladder cancer: a disease ripe for major advances.

Park JC, Hahn NM.

Clin Adv Hematol Oncol. 2014 Dec;12(12):838-45. Review.

PMID:
25674841
39.

Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, Netto GJ, Sidransky D, Hoque MO.

Cancer Prev Res (Phila). 2015 Mar;8(3):208-21. doi: 10.1158/1940-6207.CAPR-14-0251. Epub 2015 Jan 13.

40.

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G.

Eur Urol. 2015 Sep;68(3):365-71. doi: 10.1016/j.eururo.2014.12.010. Epub 2014 Dec 18.

41.

Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?

Kaimakliotis HZ, Monn MF, Cary KC, Pedrosa JA, Rice K, Masterson TA, Gardner TA, Hahn NM, Foster RS, Bihrle R, Cheng L, Koch MO.

Urol Oncol. 2014 Aug;32(6):833-8. doi: 10.1016/j.urolonc.2014.03.008. Epub 2014 Jun 18.

PMID:
24954925
42.

Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.

Albany C, Hahn NM.

Asian J Androl. 2014 May-Jun;16(3):359-63. doi: 10.4103/1008-682X.126400. Review.

43.

Novel bone-targeting agents in prostate cancer.

Albany C, Hahn NM.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):112-8. doi: 10.1038/pcan.2014.12. Epub 2014 Mar 25. Review.

PMID:
24662963
44.

Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.

Hahn NM, Yiannoutsos CT, Kirkpatrick K, Sharma J, Sweeney CJ.

Clin Genitourin Cancer. 2014 Feb;12(1):33-40.e4. doi: 10.1016/j.clgc.2013.07.002. Epub 2013 Oct 12.

PMID:
24126237
45.

EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder.

Alexander RE, Montironi R, Lopez-Beltran A, Williamson SR, Wang M, Post KM, Sen JD, Arnold AK, Zhang S, Wang X, Koch MO, Hahn NM, Masterson TA, MacLennan GT, Davidson DD, Compérat E, Cheng L.

Mod Pathol. 2014 Jan;27(1):107-12. doi: 10.1038/modpathol.2013.132. Epub 2013 Jul 26.

46.

Novel markers of squamous differentiation in the urinary bladder.

Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN, Grignon DJ, Idrees MT, Emerson RE, Zhou XJ, Zhang S, Baldridge LA, Hahn NM, Wang M, Koch MO, Cheng L.

Hum Pathol. 2013 Oct;44(10):1989-97. doi: 10.1016/j.humpath.2013.04.005. Epub 2013 Jun 24.

PMID:
23806524
47.

Elevated phospholipase A2 activities in plasma samples from multiple cancers.

Cai H, Chiorean EG, Chiorean MV, Rex DK, Robb BW, Hahn NM, Liu Z, Loehrer PJ, Harrison ML, Xu Y.

PLoS One. 2013;8(2):e57081. doi: 10.1371/journal.pone.0057081. Epub 2013 Feb 22.

48.

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M, Vogelzang NJ, Kocs D, McKenney SA, Melnyk AM Jr, Hutson TE, Rauch M, Wang Y, Asmar L, Sonpavde G.

Clin Genitourin Cancer. 2013 Jun;11(2):175-81. doi: 10.1016/j.clgc.2012.10.001. Epub 2012 Dec 8.

PMID:
23228446
49.

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD.

J Clin Oncol. 2012 Dec 10;30(35):4416-26. doi: 10.1200/JCO.2012.42.4358. Epub 2012 Nov 13. Review.

PMID:
23150697
50.

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.

Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD.

J Natl Cancer Inst. 2012 Dec 5;104(23):1837-40. doi: 10.1093/jnci/djs435. Epub 2012 Oct 23. Review.

PMID:
23093559

Supplemental Content

Support Center